Catálogo de publicaciones - revistas
Annals of Pharmacotherapy
Resumen/Descripción – provisto por la editorial en inglés
Annals of Pharmacotherapy is a peer-reviewed journal that advances pharmacotherapy throughout the world by publishing high-quality research and review articles to achieve the most desired health outcomes.The articles provide cutting-edge information about the most efficient, safe and cost-effective pharmacotherapy for the treatment and prevention of various illnesses. This journal is a member of the Committee on Publication Ethics (COPE).Palabras clave – provistas por la editorial
No disponibles.
Disponibilidad
| Institución detectada | Período | Navegá | Descargá | Solicitá |
|---|---|---|---|---|
| No detectada | desde ene. 1999 / hasta dic. 2023 | SAGE Journals |
Información
Tipo de recurso:
revistas
ISSN impreso
1060-0280
ISSN electrónico
1542-6270
Editor responsable
SAGE Publishing (SAGE)
País de edición
Estados Unidos
Fecha de publicación
1967-
Cobertura temática
Tabla de contenidos
doi: 10.1345/aph.1e345
Book Review: Handbook of Basic Pharmacokinetics…Including Clinical Applications: 6th Edition
William R Ravis
Palabras clave: Pharmacology (medical).
Pp. 2185-2185
Therapeutic Options for Adult Patients With Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Narrative Review
Daniel B. Chastain
; Kelly L. Covert; Patrick J. Tu; Steven McDougal; Bryan P. White; David Cluck
<jats:sec><jats:title>Objective:</jats:title><jats:p> To compare the efficacy of antimicrobial therapies used in the management of persistent methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. </jats:p></jats:sec><jats:sec><jats:title>Data Sources:</jats:title><jats:p> A literature search using the PubMed database (inception to December 2022) was conducted using the search terms “ Staphylococcus aureus bacteremia,” “methicillin-susceptible Staphylococcus aureus bacteremia,” “persistent methicillin-susceptible Staphylococcus aureus bacteremia,” and “refractory methicillin-susceptible Staphylococcus aureus bacteremia .” In addition, therapeutic agents which could be used as treatment for MSSA including “nafcillin,” “oxacillin,” “cefazolin,” “ceftaroline,” “gentamicin,” “rifampin,” and “daptomycin” were also combined with the aforementioned search terms to capture data using these agents. </jats:p></jats:sec><jats:sec><jats:title>Study Selection/Data Extraction:</jats:title><jats:p> Clinical data were limited to those published in the English language. Articles and abstracts were considered for inclusion in addition to ongoing trials identified through ClinicalTrials.gov. </jats:p></jats:sec><jats:sec><jats:title>Data Synthesis:</jats:title><jats:p> A total of 78 articles were reviewed including 17 in vitro or animal model studies and 39 studies including patient data. The remaining 22 articles included guidelines, review articles, and editorials. Recent data evaluating use of dual β-lactam regimens for persistent MSSA bacteremia were limited to 8 case reports or case series. </jats:p></jats:sec><jats:sec><jats:title>Relevance to Patient Care and Clinical Practice:</jats:title><jats:p> At present, there is little guidance on how to best manage patients with persistent MSSA bacteremia. This narrative review collates the available data to assist clinicians in selecting the best possible antimicrobial regimen when facing this clinical conundrum. </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> Modification of antimicrobial therapy, in conjunction with source control and infectious diseases consultation, may all be necessary to sterilize blood cultures in patients with persistent MSSA bacteremia. </jats:p></jats:sec>
Palabras clave: Pharmacology (medical).
Pp. 106002802311588